+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The prognostic significance of residual diseases, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

The prognostic significance of residual diseases, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

Gynecologic Oncology 56(2): 175-180

Survival was evaluated in 455 patients with FIGO stage III invasive ovarian cancer managed between 1983 and 1991. Median follow-up was 73 months. The prognostic significance of clinical and histopathological variables was evaluated. In Cox multivariate analysis, FIGO substage was an independent prognostic factor with a relative hazard (RH) of 1.2 and 1.7 for substage IIIB and IIIC, respectively (P = 0.013). Size of residual disease after surgery was a stronger factor with an RH of 1.2 and 2.4 for residual disease of 0 to 2 cm and more than 2 cm, respectively (P lt 0.001). Histologic type had prognostic significance because patients with endometrioid tumors did best, those with mixed, serous, and unclassified tumors had an RH of 1.5 to 1.9, and those with mucinous and clear cell tumors had an RH of 5.4 to 7 (P lt 0.001). Grade, ascites, and age had also independent significance. Grade had an RH of 2.5 for grade 2 plus 3 (P lt 0.001), ascites had an RH of 1.4 (P 0.018), and age had an RH of 1.7 and 2.4 for age 40 to 70 years and above 70 years, respectively (P lt 0.001).

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 009611204

Download citation: RISBibTeXText

PMID: 7896181

Related references

Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology 140(2): 215-220, 2016

Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. International Journal of Gynecological Cancer 22(3): 380-385, 2012

Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network. Annals of Surgical Oncology 23(4): 1279-1286, 2016

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of Surgical Oncology 17(6): 1642-1648, 2010

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. Obstetrics and Gynecology International 2015: 464123, 2015

The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?. Gynecologic Oncology 142(2): 243-247, 2017

Prognostic significance of cell DNA content in early-stage ovarian cancer (Figo stages I and II/A) by means of automatic image cytometry. International Journal of Cancer 56(2): 167-172, 1994

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology 2019, 2019

Treatment of ovarian cancer at FIGO stage III and IV--prognostic factors for patients receiving neoadjuvant chemotherapy. Nihon Sanka Fujinka Gakkai Zasshi 45(7): 665-672, 1993

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. European Journal of Surgical Oncology 37(11): 971-977, 2011

Quantitative pathological variables as prognostic factors for overall survival in Danish patients with FIGO stage III ovarian cancer. International Journal of Gynecological Cancer 6(3): 168-174, 1996

Prognostic Factors in Patients Undergoing Primary Cytoreductive Surgery for FIGO Stage IIIC Ovarian, Tubal or Peritoneal Cancer. Journal of Obstetrics and Gynaecology Canada 40(4): 447-453, 2017

A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecologic Oncology 104(3): 607-611, 2006

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. British Journal of Cancer 79(11-12): 1746-1751, 1999

Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment. International Journal of Gynecological Cancer 5(4): 262-268, 1995